The biologic drugs currently available are designed to hit one or two targets, but even so, they can still activate other cells and spark adverse effects. Tentarix Biotherapeutics is developing ...

AbbVie and Tentarix Biotherapeutics have announced a multi-year collaboration aimed at developing biologic candidates in oncology and immunology, with the deal worth over $64m. The partnership will ...

Aug 15 (Reuters) - Gilead Sciences GILD.O said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop therapies for cancer and inflammatory diseases.

Gilead Sciences announced three multi-year collaborations with Tentarix Biotherapeutics to develop cancer and inflammatory disease therapies. As part of the agreement unveiled Tuesday, Gilead will ...

SAN DIEGO--(BUSINESS WIRE)--Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two ...

SAN DIEGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara ...

SAN DIEGO, September 30, 2025--(BUSINESS WIRE)--Tentarix Biotherapeutics LP, a biotechnology company developing best-in-class, targeted and conditionally active multispecific biologics, today ...

AbbVie Inc. and Tentarix Biotherapeutics announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and ...

SAN DIEGO--(BUSINESS WIRE)--Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein ...

Tentarix’s platform creates next generation antibody-based multifunctional biotherapeutics that achieve unprecedented specificity and unique activity. Such products can conditionally activate or ...